Health TrialsbyHealthPanel

Natural History of Hypereosinophilia and Hypereosinophilic Syndromes

ConditionsEosinophiliaHypereosinophilic Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity Hospital, Lille

About this trial

Unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES) are heterogeneous regarding the organ involvements (heart, lungs, skin, .. or none), the evolutionary profiles, the response to treatments.

Underlying mechanisms are largely unknown and may associate genetic predisposing factors (germinal ? somatic?), environmental factors (alimentation, tobacco use, hormones, infections, ..) The COHESion study aims to study all clinical and biological characteristics of HE/HES patients and their evolutionary profiles, with a focus on genetic factors and the mechanisms supporting transitory or persistant chronic HE/HES (in absence of any well identified extrinsic trigger like drugs, parasitosis, ..)

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

With the diagnosis criteria of hyperosinophlia OR hypereosinophilic syndrome OR specific organ eosinophilic disease according to the consensus conference of the International Cooperative Working Group on Eosinophil Disorders (ICOG-EO)

With an AEC > 1500/mm3 or organ damage related to the presence of eosinophils in the tissues or organs whatever the context (idiopathic, clonal or reactive, including drug-related, parasitic or allergic)

HES diagnosis since 2005/01/01

Patients socially insured

Disqualifiers

Known HIV infection

Not socially insured

Person unable to receive a enlighten information

Person who refuse to sign the consent

Trial population

Patients with Hypereosinophilia and Hypereosinophilic Syndromes

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Biological sample

    Biological/Vaccine

    Additional blood samples for biobanking

Treatment groups

600 Participants
are divided into 1 treatment group
Group A: Eosinophilia/Hypereosinophilic syndrome1 intervention

Trial outcomes

Primary outcomes

1

Frequency of the different clinical manifestations at time of diagnosis and during follow-up of the hypereosinophilic syndrome (HES)

The primary objective of the study is to describe the frequency of the different clinical manifestations at diagnosis and during follow-up of the hypereosinophilic syndrome (HES/HE). The primary endpoint is the frequency of the different clinical manifestations and/or organs damage related to hypereosinophilia.

Time frame
10 years

Secondary outcomes

1

Frequency of the evolutionary profiles

Frequency of the different evolutionary profiles.

Time frame
10 years
2

Frequency of complications depending of the type of HES

Frequency of complications (organ damages) depending on the type of HES (idiopathic, reactive, clonal…).

Time frame
10 years
3

Frequency of organ damage profiles before and after 18 years old.

Describe the characteristics of pediatrics HE/HES vs adult HE/HES.

Time frame
10 years
4

Frequency of clinical complications profiles before and after 18 years old.

Clinical characteristics of pediatrics HE/HES vs adult HE/HES.

Time frame
10 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Lille

Lead sponsor

Source ClinicalTrials.gov
Apply now